Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
Related Questions
What are your top takeaways in Medical Oncology from SABCS 2025?
How, if at all, does the spectrum of HER2 positivity impact efficacy of T-DXd in the frontline setting?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
How would you approach treatment selection for an elderly woman with de novo metastatic HER2+ breast cancer with lung and brain mets?
For patients with PI3K mutated metastatic breast cancer who progress on a PI3K inhibitor, will you use an alternative PI3K inhibitor subsequently?
Is the currently available data from INAVO sufficient to adopt this as a new standard of care for all patients or are you awaiting overall survival and/or PROs?
What are your top takeaways in Radiation Oncology from SABCS 2025?
In a patient with de novo stage IV breast carcinoma harboring an RB1 Q395* (nonsense) mutation, would treatment with a CDK4/6 inhibitor be appropriate, or should it be avoided due to likely resistance?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
Do you continue ovarian suppression for metastatic hormone-positive breast cancer patients who are premenopausal, regardless of line of therapy?
